Company profile: Onco-NX
1.1 - Company Overview
Company description
- Provider of drug discovery research dedicated to identifying new promising anticancer agents as a University of Salford spin-out company.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Onco-NX
Totus Medicines
HQ: United States
Website
- Description: Provider of AI/ML-driven small-molecule drug discovery using innovative DNA-encoded covalent libraries. Offers the Totus Platform combining AI/ML, cellular analysis, and covalent chemistry for high-throughput genome-wide screening, plus an oncology pipeline including TOS-358, a PI3Kα inhibitor for breast, colorectal, and lung cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Totus Medicines company profile →
Tesaro
HQ: United States
Website
- Description: Provider of oncology-focused biopharmaceutical solutions dedicated to improving the lives of cancer patients, leveraging management expertise to identify, acquire and develop promising drug candidates and to commercialize safer, more effective cancer therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tesaro company profile →
Sesen Bio
HQ: United States
Website
- Description: Provider of protein-based therapeutics focused on improving human health, including Vicineum, a locally administered targeted fusion protein for BCG-unresponsive non-muscle invasive bladder cancer, and VB6-845d, an anti-PSMA humabody-deBouganin fusion protein designed for tumor cell killing and overcoming drug resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sesen Bio company profile →
Izotropic
HQ: United States
Website
- Description: Provider of breast CT imaging solutions, offering a high-resolution, 3D Breast CT Imaging System that captures approximately 500 images in a 10-second scan without compression; a robotic-guided Breast CT Biopsy System for imaging and sampling suspicious lesions and tumors for pathology testing; and Breast CT–based breast density measurement using 3D images and algorithms to estimate glandular volumes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Izotropic company profile →
Adaptive Biotechnologies
HQ: United States
Website
- Description: Provider of immune system-based products to diagnose and treat disease, including clonoSEQ, an FDA-cleared service for detecting and monitoring minimal residual disease in bone marrow from patients with certain blood cancers; immunoSEQ, a tool for profiling and monitoring the adaptive immune response, aiding research across multiple disease areas; and T-Detect COVID, a diagnostic using T cell markers, authorized for emergency use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptive Biotechnologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Onco-NX
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Onco-NX
2.2 - Growth funds investing in similar companies to Onco-NX
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Onco-NX
4.2 - Public trading comparable groups for Onco-NX
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →